An Open-label, Phase I Trial to Determine the Maximum-tolerated Dose and Investigate Safety, Pharmacokinetics, and Efficacy of BI 754091 in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2018
At a glance
- Drugs BI 754091 (Primary)
- Indications Bladder cancer; Breast cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 16 Apr 2018 Planned End Date changed from 29 May 2019 to 30 Mar 2021.
- 16 Apr 2018 Planned primary completion date changed from 29 May 2019 to 30 Mar 2021.
- 26 Jan 2018 Planned number of patients changed from 45 to 105.